SG11201807548SA - Inducible binding proteins and methods of use - Google Patents
Inducible binding proteins and methods of useInfo
- Publication number
- SG11201807548SA SG11201807548SA SG11201807548SA SG11201807548SA SG11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san francisco
- pct
- applicant
- street
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- RBSXHDIPCIWOMG-UHFFFAOYSA-N 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea Chemical compound CCS(=O)(=O)C=1N=C2C=CC=CN2C=1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 RBSXHDIPCIWOMG-UHFFFAOYSA-N 0.000 abstract 1
- 241000721662 Juniperus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305092P | 2016-03-08 | 2016-03-08 | |
| PCT/US2017/021435 WO2017156178A1 (en) | 2016-03-08 | 2017-03-08 | Inducible binding proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807548SA true SG11201807548SA (en) | 2018-09-27 |
Family
ID=59789722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807548SA SG11201807548SA (en) | 2016-03-08 | 2017-03-08 | Inducible binding proteins and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180134789A1 (ja) |
| EP (1) | EP3426689A4 (ja) |
| JP (3) | JP7195927B2 (ja) |
| KR (2) | KR102501921B1 (ja) |
| CN (1) | CN109071667A (ja) |
| AU (1) | AU2017229687A1 (ja) |
| BR (1) | BR112018068189A2 (ja) |
| CA (1) | CA3016165A1 (ja) |
| IL (1) | IL261432B2 (ja) |
| MA (1) | MA43816A (ja) |
| MX (1) | MX2018010824A (ja) |
| SG (1) | SG11201807548SA (ja) |
| TW (2) | TW202302631A (ja) |
| WO (1) | WO2017156178A1 (ja) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6688551B2 (ja) | 2015-05-21 | 2020-04-28 | ハープーン セラピューティクス，インク． | 三重特異性結合タンパク質と使用方法 |
| WO2017087789A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| IL263102B2 (en) * | 2016-05-20 | 2023-11-01 | Harpoon Therapeutics Inc | A serum albumin-binding protein with a single site |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| BR112019010604A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteína de ligação ao antígeno da membrana próstata-específico |
| KR20190087539A (ko) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | Psma 표적화 삼중특이성 단백질 및 사용 방법 |
| WO2018160671A1 (en) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US20200115461A1 (en) * | 2017-05-03 | 2020-04-16 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
| JP2020534811A (ja) | 2017-09-08 | 2020-12-03 | マベリック セラピューティクス， インコーポレイテッドＭａｖｅｒｉｃｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｆｃ領域を含有する条件的に活性化された結合部分 |
| SG11202002089RA (en) * | 2017-09-08 | 2020-04-29 | Maverick Therapeutics Inc | Constrained conditionally activated binding proteins |
| KR102429747B1 (ko) | 2017-10-13 | 2022-08-05 | 하푼 테라퓨틱스, 인크. | B 세포 성숙화 항원 결합 단백질 |
| EP3694529A4 (en) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHOD OF USE |
| WO2019089472A1 (en) * | 2017-11-01 | 2019-05-09 | Nantbio, Inc. | Il8 blocking emt pathway and overcoming cancer stem cells |
| CN110218253B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用 |
| CN110218256B (zh) * | 2018-03-02 | 2020-12-08 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用 |
| SG11202011308VA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| CN112513083A (zh) * | 2018-05-14 | 2021-03-16 | 哈普恩治疗公司 | 用于条件性激活免疫球蛋白分子的结合部分 |
| SG11202011349PA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable interleukin-2 polypeptides and methods of use thereof |
| EP3810624A4 (en) * | 2018-06-22 | 2022-07-06 | Cugene Inc. | CYTOKINE-BASED BIOACTIVABLE MEDICATIONS AND METHODS OF USE THEREOF |
| US20210309756A1 (en) | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| CA3126707A1 (en) * | 2019-01-29 | 2020-08-06 | Gritstone Bio, Inc. | Multispecific binding proteins |
| CN114390938A (zh) * | 2019-03-05 | 2022-04-22 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| US20220144949A1 (en) | 2019-03-05 | 2022-05-12 | Takeda Pharmaceutical Limited Company | CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS |
| MX2021013766A (es) | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Restos de separacion y metodos de uso de los mismos. |
| WO2021097060A1 (en) * | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Pro immune modulating molecule comprising a clustering moiety |
| JP7392145B2 (ja) * | 2019-12-20 | 2023-12-05 | 山東博安生物技術股▲ふん▼有限公司 | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム |
| CN114945597A (zh) * | 2020-01-17 | 2022-08-26 | 艾提欧生物疗法有限公司 | 降低脱靶毒性的前抗体 |
| CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
| EP4132656A1 (en) | 2020-04-09 | 2023-02-15 | CytomX Therapeutics, Inc. | Compositions containing activatable antibodies |
| WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
| AU2021329290A1 (en) | 2020-08-17 | 2023-04-13 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| KR20230058377A (ko) * | 2020-08-18 | 2023-05-03 | 온칠리스 파마 인코포레이티드 | 변형된 세린 프로테아제 프로단백질 |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| WO2022125576A1 (en) | 2020-12-09 | 2022-06-16 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| AU2022255387A1 (en) | 2021-04-06 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Therapeutic methods using constrained conditionally activated binding proteins |
| EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
| WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
| WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| ES2358427T3 (es) * | 2003-10-16 | 2011-05-10 | Micromet Ag | Elementos de unión a cd-3 desinmunizados multiespecíficos. |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| EP2609112B1 (en) * | 2010-08-24 | 2017-11-22 | Roche Glycart AG | Activatable bispecific antibodies |
| US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| BR122016016837A2 (pt) * | 2011-05-21 | 2019-08-27 | Macrogenics Inc | moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3 |
| AR087020A1 (es) | 2011-07-01 | 2014-02-05 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos |
| US9035029B2 (en) | 2012-02-27 | 2015-05-19 | Boehringer Ingelheim International Gmbh | CX3CR1-binding polypeptides comprising immunoglobulin single variable domains |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US20150037334A1 (en) | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| MX2015016963A (es) * | 2013-06-10 | 2016-08-08 | Dana Farber Cancer Inst Inc | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. |
| SG11201607983YA (en) * | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| WO2017087789A1 (en) * | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US20210309756A1 (en) * | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2017
- 2017-03-08 KR KR1020187029014A patent/KR102501921B1/ko active IP Right Grant
- 2017-03-08 AU AU2017229687A patent/AU2017229687A1/en not_active Abandoned
- 2017-03-08 JP JP2018547940A patent/JP7195927B2/ja active Active
- 2017-03-08 WO PCT/US2017/021435 patent/WO2017156178A1/en active Application Filing
- 2017-03-08 SG SG11201807548SA patent/SG11201807548SA/en unknown
- 2017-03-08 IL IL261432A patent/IL261432B2/en unknown
- 2017-03-08 TW TW111119065A patent/TW202302631A/zh unknown
- 2017-03-08 BR BR112018068189A patent/BR112018068189A2/pt unknown
- 2017-03-08 CN CN201780028480.4A patent/CN109071667A/zh active Pending
- 2017-03-08 CA CA3016165A patent/CA3016165A1/en active Pending
- 2017-03-08 EP EP17764037.2A patent/EP3426689A4/en active Pending
- 2017-03-08 TW TW106107861A patent/TW201808990A/zh unknown
- 2017-03-08 MA MA043816A patent/MA43816A/fr unknown
- 2017-03-08 MX MX2018010824A patent/MX2018010824A/es unknown
- 2017-03-08 KR KR1020237005284A patent/KR20230041739A/ko not_active Application Discontinuation
- 2017-10-06 US US15/727,423 patent/US20180134789A1/en not_active Abandoned
-
2022
- 2022-05-18 JP JP2022081366A patent/JP7293456B2/ja active Active
-
2023
- 2023-06-07 JP JP2023093681A patent/JP2023123519A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017156178A1 (en) | 2017-09-14 |
| EP3426689A1 (en) | 2019-01-16 |
| TW201808990A (zh) | 2018-03-16 |
| MX2018010824A (es) | 2019-05-15 |
| IL261432B2 (en) | 2024-03-01 |
| AU2017229687A1 (en) | 2018-09-20 |
| JP2022140856A (ja) | 2022-09-28 |
| KR20180120245A (ko) | 2018-11-05 |
| MA43816A (fr) | 2018-11-28 |
| JP2019513014A (ja) | 2019-05-23 |
| EP3426689A4 (en) | 2020-01-15 |
| KR102501921B1 (ko) | 2023-02-21 |
| RU2018134949A (ru) | 2020-04-08 |
| JP7195927B2 (ja) | 2022-12-26 |
| IL261432A (en) | 2018-10-31 |
| RU2018134949A3 (ja) | 2020-08-14 |
| TW202302631A (zh) | 2023-01-16 |
| CA3016165A1 (en) | 2017-09-14 |
| US20180134789A1 (en) | 2018-05-17 |
| JP7293456B2 (ja) | 2023-06-19 |
| IL261432B1 (en) | 2023-11-01 |
| KR20230041739A (ko) | 2023-03-24 |
| JP2023123519A (ja) | 2023-09-05 |
| BR112018068189A2 (pt) | 2019-02-05 |
| CN109071667A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807548SA (en) | Inducible binding proteins and methods of use | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201811600PA (en) | Pseudotyped oncolytic viral delivery of therapeutic polypeptides | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201805375PA (en) | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof |